Sökning: L773:1479 6821 OR L773:1351 0088 >
Peptide receptor ra...
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3 : a multicenter cohort study
-
- Carlsen, Esben Andreas (författare)
- Rigshosp, Dept Clin Physiol Nucl Med & PET, Copenhagen, Denmark;Univ Copenhagen, Dept Biomed Sci, Cluster Mol Imaging, Copenhagen, Denmark
-
- Fazio, Nicola (författare)
- European Inst Oncol IRCCS, Div Gastrointestinal Med Oncol & Neuroendocrine T, IEO, Milan, Italy
-
- Granberg, Dan (författare)
- Karolinska Institutet,Uppsala universitet,Onkologisk endokrinologi
-
visa fler...
-
- Grozinsky-Glasberg, Simona (författare)
- Hadassah Hebrew Univ, Dept Endocrinol & Metab, Neuroendocrine Tumor Unit, Med Ctr, Jerusalem, Israel
-
- Ahmadzadehfar, Hojjat (författare)
- Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
-
- Grana, Chiara Maria (författare)
- European Inst Oncol IRCCS, Div Nucl Med, IEO, Milan, Italy
-
- Zandee, Wouter T. (författare)
- Erasmus MC, Rotterdam, Netherlands
-
- Cwikla, Jaroslaw (författare)
- Univ Warmia & Mazury, Med Sch, Olsztyn, Poland
-
- Walter, Martin A. (författare)
- Univ Hosp Geneva, Dept Nucl Med, Geneva, Switzerland
-
- Oturai, Peter Sandor (författare)
- Rigshosp, Dept Clin Physiol Nucl Med & PET, Copenhagen, Denmark
-
- Rinke, Anja (författare)
- Univ Hosp Giess & Marburg, Dept Gastroenterol, Marburg, Germany
-
- Weaver, Andrew (författare)
- Churchill Hosp, Dept Oncol, Oxford, England
-
- Frilling, Andrea (författare)
- Imperial Coll London, Dept Surg & Canc, London, England
-
- Gritti, Sara (författare)
- European Inst Oncol IRCCS, Div Gastrointestinal Med Oncol & Neuroendocrine T, IEO, Milan, Italy
-
- Arveschoug, Anne Kirstine (författare)
- Aarhus Univ Hosp, Dept Nucl Med & PET, Aarhus, Denmark
-
- Meirovitz, Amichay (författare)
- Hadassah Hebrew Univ, Med Ctr, Dept Oncol, Jerusalem, Israel;Hadassah Hebrew Univ, Med Ctr, Radiat Therapy Unit, Jerusalem, Israel
-
- Knigge, Ulrich (författare)
- Univ Copenhagen, Dept Biomed Sci, Cluster Mol Imaging, Copenhagen, Denmark;Rigshosp, Dept Surg Gastroenterol, Copenhagen, Denmark;Rigshosp, Dept Clin Endocrinol, Copenhagen, Denmark
-
- Sorbye, Halfdan (författare)
- Haukeland Hosp, Dept Oncol, Bergen, Norway;Univ Bergen, Dept Clin Sci, Bergen, Norway
-
visa färre...
-
(creator_code:org_t)
- Bioscientifica, 2019
- 2019
- Engelska.
-
Ingår i: Endocrine-Related Cancer. - : Bioscientifica. - 1351-0088 .- 1479-6821. ; 26:2, s. 227-239
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine tumors grade 1-2 (G1-G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN G3) is largely unknown. We therefore aimed to assess the benefits and side effects of PRRT in patients with GEP NEN G3. We performed a retrospective cohort study at 12 centers to assess the efficacy and toxicity of PRRT in patients with GEP NEN G3. Outcomes were response rate, disease control rate, progression-free survival (PFS), overall survival (OS) and toxicity. We included 149 patients (primary tumor: pancreatic n = 89, gastrointestinal n = 34, unknown n = 26). PRRT was first-line (n = 30), second-line (n = 62) or later-line treatment (n = 57). Of 114 patients evaluated, 1% had complete response, 41% partial response, 38% stable disease and 20% progressive disease. Of 104 patients with documented progressive disease before PRRT, disease control rate was 69%. The total cohort had median PFS of 14 months and OS of 29 months. Ki-67 21-54% (n = 125) vs Ki-67 >= 55% (n = 23): PFS 16 vs 6 months (P < 0.001) and OS 31 vs 9 months (P < 0.001). Well (n = 60) vs poorly differentiated NEN (n = 62): PFS 19 vs 8 months (P < 0.001) and OS 44 vs 19 months (P < 0.001). Grade 3-4 hematological or renal toxicity occurred in 17% of patients. This large multicenter cohort of patients with GEP NEN G3 treated with PRRT demonstrates promising response rates, disease control rates, PFS and OS as well as toxicity in patients with mainly progressive disease. Based on these results, PRRT may be considered for patients with GEP NEN G3.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- neuroendocrine tumors
- neuroendocrine carcinoma
- neuroendocrine neoplasm
- high-grade
- peptide receptor radionuclide therapy
- radiolabeled somatostatin analogues
- (177)Lutetium
- (90)Yttrium
- progression-free survival
- overall survival
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Carlsen, Esben A ...
-
Fazio, Nicola
-
Granberg, Dan
-
Grozinsky-Glasbe ...
-
Ahmadzadehfar, H ...
-
Grana, Chiara Ma ...
-
visa fler...
-
Zandee, Wouter T ...
-
Cwikla, Jaroslaw
-
Walter, Martin A ...
-
Oturai, Peter Sa ...
-
Rinke, Anja
-
Weaver, Andrew
-
Frilling, Andrea
-
Gritti, Sara
-
Arveschoug, Anne ...
-
Meirovitz, Amich ...
-
Knigge, Ulrich
-
Sorbye, Halfdan
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Endocrine-Relate ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet